Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, in conjunction with its portfolio company, LifeSpan Biosciences, Inc., (LSBio) has acquired Scicons, based in Hungary. The Company is a manufacturer and developer of monoclonal antibodies primarily for the research and diagnostic markets. Terms of the transaction were not disclosed.
The founder-led-and-owned Scicons (www.scicons.eu) was founded in 1988 and specializes in monoclonal antibody technology, focused on identifying the presence of double-stranded RNA molecules. These reagents have been used extensively to characterize dsRNA complexes produced during viral infection, as well as to detect dsRNA impurities in mRNA manufactured for therapeutic applications. The new acquisition brings a strong catalog of monoclonal antibodies together with an already expansive portfolio across the LSBio companies. Many of the largest academic research institutions, diagnostic providers and biotech companies leverage Scicons products in their production and research workflow on a regular basis.
“We are very excited to add the Scicons portfolio into the LSBio family of companies.” said Dr. Heather Holemon, CEO of LSBio. “It adds to LSBio’s unique and differentiated content. These products are of extremely high-quality as demonstrated by their broad customer adoption and the number of mentions in peer-reviewed journals. We will be able to fold their manufacturing seamlessly into our monoclonal production pipeline at our ISO-certified Susteren site.”
Said Bob Dunn, Managing Partner, TSCP, “We’re excited to be partnering with the management team of LSBio and the founders of Scicons to bring their business into the LSBio family. These products complement our existing antibody portfolio and customer base nicely.” Added J.C. Wetzel, Director, TSCP, “Scicons represents the fourth acquisition and sixth brand we have acquired as part of the LSBio platform. We will continue building LSBio into a world-class provider of reagents to the research, diagnostic and biotech markets via both organic and inorganic strategies.”
